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Abstract
Introduction—Statin medications have anti-inflammatory effects. We sought to determine
whether statin use in persons with inflammatory bowel disease (IBD) was associated with reduced
rates of steroid use or other markers of disease activity.
Methods—We performed a retrospective cohort study using administrative data. Statin users
with IBD were compared to statin-unexposed IBD subjects. The primary outcome was an oral
steroid prescription; secondary outcomes included anti-TNF initiation, hospitalization, or
abdominal surgery. Cox proportional hazard models were used to estimate hazard ratios (HR)
adjusted for potential confounders.
Results—The study cohort included 1,986 statin-exposed and 9,871 unexposed subjects. Statin
use was associated with an 18% reduction in the rate of steroid initiation [HR 0.82 (95% CI 0.71,
0.94)]. A statistically significant result was seen with atorvastatin only [HR 0.76 (95% CI 0.60,
0.96)]. Statins were associated with a reduced rate of steroids in ulcerative colitis [HRs 0.75 (95%
CI 0.62, 0.91)], but not in Crohn’s disease [HR 0.91 (95% CI 0.74, 1.12)]. Statin use was
associated with reduced hazard of anti-TNF use [HR 0.72 (95% CI 0.46, 1.11)], abdominal
surgery [HR 0.80 (95% CI 0.63, 1.02)], and hospitalization [HR 0.88 (95% CI 0.74, 1.05)], but
these results did not reach statistical significance.
Conclusion—In this large retrospective cohort study, statin use amongst persons with IBD was
associated with reduced use of oral steroids, particularly for UC. Prospective clinical trials are
needed to confirm whether adjuvant treatment of IBD with statin drugs may spare
immunosuppressant therapy or ameliorate flares.
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Introduction
Inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis
(UC), affect 1-1.5 million Americans (1, 2). Both UC and Crohn’s are associated with
substantial morbidity, including frequent hospitalization and surgery (3, 4), reductions in
quality of life (5), an increased risk of colorectal cancer (6), and increased mortality (7). The
current medical armamentarium for IBD includes drugs that are either incompletely
effective, have serious potential adverse effects, are difficult to administer, or are very
expensive. The recent development and use of biologic therapies in IBD has brought
increased effectiveness (8, 9), but also concerns about safety (10, 11), and the associated
increase in the cost of treating IBD (12, 13). Pharmacoepidemiology studies that explore
novel uses of existing medications could lead to the identification of safe and inexpensive
treatment options for patients with IBD.
Statin drugs are widely used worldwide for treatment of hyperlipidemia (14, 15). In addition
to cholesterol-lowering, statins reduce many of the mediators involved in IBD-specific
inflammation including C-reactive protein, interferon gamma, interleukins 6 and 8, and NF-
kappa B (16-18). Furthermore, studies in animal models of IBD suggest that statins can
attenuate colitis (19, 20). In humans, a few small studies suggest a possible beneficial effect
of statins. A randomized controlled trial of atorvastatin vs. placebo in UC patients reported a
reduction in disease activity and a higher rate of remission in patients treated with
atorvastatin compared to placebo (21). A small uncontrolled trial of atorvastatin treatment in
CD patients demonstrated a measurable reduction in pro-inflammatory markers, and a non-
statistically significant decrease in disease activity on treatment (22). However, a second
open-label trial of pravastatin and rosuvastatin in CD did not show a benefit of statin therapy
(23).
Importantly, statins are associated with minimal toxicity, and are substantially less
expensive than most existing IBD therapies (<$1/day for generic versions). It is unknown
whether statins may reduce the rate of flares of disease or other important patient-related
outcomes. This study was designed to address the question of whether use of statin drugs
could result in steroid sparing and reduce IBD exacerbations in a large cohort of patients.
Materials and Methods
Study design and data source
This was a retrospective cohort study using an administrative claims database. The
MarketScan database (Thompson Reuters©) is a proprietary database that contains claims
data on over 35 million individuals covered by employer-sponsored commercial health
insurance from over 100 health plans, large employers, and government and public
organizations. Data elements include inpatient and outpatient diagnoses ((International
Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM)), procedures
(Current Procedural Terminology, 4th Edition (CPT-4)), prescription records, demographic
information, and enrollment details. Data from January 2005 to December 2007 were used
in this study. This database has been used in other epidemiologic studies of IBD (24, 25) and
statins (26), and is representative of the commercially-insured population of the US (27, 28).
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Cohort identification and assessment of exposure
We selected IBD patients initiating a statin medication and a comparator group of statin-
unexposed IBD patients using the following process. First, the entire source population
(n=35,568,227) was limited to those aged 35-64 years who met the IBD case definition: 1) at
least 1 healthcare contact associated with an ICD-9-CM diagnosis code for CD (555.xx) or
UC (556.xx) and 2) at least 1 pharmacy claim for any of the following medications:
mesalamine, olsalazine, balsalazide, sulfasalazine, 6-mercaptopurine, azathioprine, or
enteral budesonide. To qualify for the study, exposed subjects had a new prescription for
one of the six statin drugs on the US market at the time of this study (atorvastatin,
fluvastatin, lovastatin, pravastatin, rosuvastatin, or simvastatin). This “new user design” was
used to minimize bias resulting from analysis of prevalent medication use such as the
healthy user effect (29). Statin use was continuous, though gaps in prescribing dates of ≤60
days beyond days supplied were allowed (30). Subjects were excluded if they did not meet
the IBD diagnostic criteria or did not have continuous health plan enrollment and pharmacy
benefits during the 6 month pre-exposure period and the first month of the post-exposure
period.
For each new statin user, we randomly sampled statin-unexposed persons (who met the
same criteria for IBD and enrollment in the 6 month pre-exposure period) in a 5:1 ratio
using an incidence density design, matched on age (in 5 year increments) and sex. In
addition, we required unexposed persons to have received at least 1 outpatient pharmacy
claim for a non-statin prescription during the month they were matched in order to ensure a
comparator population with similar healthcare access and utilization.
After these procedures, 2,022 statin-exposed subjects and 10,110 matched unexposed
subjects were identified. Subsequently, 275 subjects were eliminated because they had
claims for either a colectomy or enterostomy (n=184) or a diagnosis of colon cancer (n=91)
in the pre-exposure period. The final study population included 1,986 exposed and 9,871
unexposed subjects (Figure 1).
Assessment of covariates of interest
In addition to demographic information on age, sex, and geographic region (Northeast,
North Central, South, and West based on US Census regions), data on potential confounders
were collected during the 6 month pre-exposure period. These covariates included type of
IBD (UC or CD, based on majority of diagnosis claims), use of other IBD medications
[aminosalicylate drugs (mesalamine, olsalazine, balsalazide, sulfasalazine), 6-
mercaptopurine (6-MP) or azathioprine, anti-TNF drugs (infliximab or adalimumab),
cholestyramine, rectal steroids (enema, suppository, or foam), methotrexate, or
cyclosporine], markers of disease severity [weight loss (ICD-9 783.2x), malnutrition (ICD-9
262.xx - 263.xx) and anemia (ICD-9 280.xx)], non-colectomy abdominal surgery (CPT
44500-44979, 49000-49999, 45000-45190, 45395-45999, 46020-46211, 46270-46288,
46700-46762, 46937-46942, 46999), comorbidities [Deyo modification of the Charlson
comorbidity index (31, 32), claims for coronary artery disease (ICD-9 410.xx – 414.xx),
stroke (ICD-9 433.xx- 435.xx), or diabetes (ICD-9 250.xx)], and markers of healthcare
utilization [number of inpatient and outpatient contacts, and endoscopic procedures (upper
or lower endoscopy, CPT codes: 43200-43259, 44360-44386, 44388-44397, or
45300-45392)].
Outcomes and censoring events
The primary outcome for this study was defined as a 1st prescription for an oral steroid (days
supplied ≥ 14), a marker of flare of disease (33). Secondary outcomes included a 1) 1st use
of an anti-TNF agent (infliximab or adalimumab, if not used in 6 months prior to cohort
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entry); 2) colectomy or other abdominal surgery (excluding outpatient anal procedures such
as hemorrhoidectomy); and 3) first hospitalization. A composite outcome was also analyzed
(i.e. any primary or secondary outcome).
Participants were censored if they experienced a lapse in plan enrollment/pharmacy benefit
> 1 month, if they stopped using a statin (for statin group only- defined as a gap of >60 days
beyond days supplied, according to a previously published definition (30)), if they started
using a statin (for the unexposed group only), or if they reached the end of study period
(December 31, 2007).
Statistical Analysis
Bivariate analysis was performed between covariates and the exposure (using chi-squared
tests for categorical variables, or Student’s t-tests for continuous variables), and the primary
outcome (using Kaplan Meier plots and log rank tests). Covariates were evaluated for
confounding and effect modification if they were significantly associated with the exposure
and outcome at an alpha of ≤ 0.2, or if they were believed to be important confounders based
on previously published data. Prior to inclusion in modeling, each variable was evaluated
with log-log plots and Schoenfeld residuals to ensure the proportional hazards assumption
was not violated.
Multivariate analysis—Cox proportional hazard modeling was performed to estimate
hazard ratios (HR) for the association between statin use and the primary and secondary
outcomes. To determine which covariates should be included in the final multivariable
models, a full model with all potential confounders was constructed. Covariates were then
removed from the model using backwards elimination with a threshold of <10% change in
beta coefficients and a likelihood ratio test p value of >0.05. The Charlson index was
retained in each model in order to ensure adjustment for comorbid illness. Because this
process was repeated iteratively for each outcome, the adjustment set differed slightly for
models for the primary and secondary outcomes. All analyses were performed with STATA
version 10.1 (College Station, TX).
Dosage, duration, and adherence analyses—For each statin preparation, a
dichotomous variable for dose was created for low and high dose, based on the mean dose
for each drug. These variables were then combined into a dichotomous high/low dose
variable for all statin-exposed subjects to test the effects of increasing dose. Duration of
statin treatment was dichotomized as ≤90 days vs. >90 days. In addition, the medication
possession ratio [MPR: calculated as: (sum of days supplied) ÷ (study days)](34) was
calculated for each exposed subject and was categorized using cutoffs of 0.80 and 0.90 to
determine whether different levels of adherence modified the effect of statin use (35).
Sensitivity analyses—We conducted a number of sensitivity analyses to further evaluate
our findings, including restricting the population to: 1) subjects meeting a more stringent
diagnosis criteria prior to study entry: ≥ 4 IBD diagnosis claims + ≥ 1 IBD prescription; 2)
subjects between the ages of 35-50; 3) subjects without pre-exposure diagnoses of coronary
artery disease, diabetes, or stroke; 4) subjects taking statins for >30 days; and 5) subjects
who did not receive steroids in the pre-exposure period.
Ethical Considerations
The study protocol was granted an exemption by the Institutional Review Board at
University of North Carolina because it involved the use of de-identified data.
Crockett et al. Page 4















The study cohort included 1,986 statin-exposed subjects and 9,871 matched unexposed
subjects (Figure 1, Table 1). Age and sex distributions were expectedly similar given the
matching design. Study groups differed based on comorbidities (a higher proportion of
statin-exposed subjects had diagnoses of coronary artery disease, diabetes, and stroke).
Statin-exposed subjects had slightly more outpatient contacts and hospitalizations.
Medication use and endoscopy utilization was similar between groups.
Primary outcome
The absolute frequencies of primary and secondary outcomes are included in Supplementary
Table A. The crude incidence of steroid use in the post exposure period was 20.9 per 100
patient years for all study subjects. Overall, statin exposure was associated with an 18%
reduction in the rate of receiving steroids [HR 0.82 (95% CI 0.71, 0.94)], after adjusting for
the Charlson comorbidity index, pre-exposure use of anti-TNF, 5-ASA, 6-MP/azathioprine,
or rectal steroids, the number of outpatient contacts and hospitalization prior to exposure
(Table 2, Figure 2). When stratified by disease type, statins were associated with a reduced
rate of steroid use in UC [HRs 0.75 (95% CI 0.62, 0.91), but not CD. The hazard ratios of
other covariates in the model are presented in Supplementary Table B.
Secondary outcomes
Statin exposure was associated with a trend towards decreased rate of anti-TNF agent use,
abdominal surgery, and hospitalization for overall IBD and after stratifying by disease type
(CD versus UC), though only the association between statin use and abdominal surgery in
CD was statistically significant (Table 3). Statin exposure was significantly associated with
a reduction of the composite outcome for overall IBD.
Dose, duration, and adherence analysis
Dose, duration, and adherence to statin medication were examined to determine whether
there was evidence of a dose response effect (Table 4). Compared to unexposed persons,
those taking high dose statins had the lowest rate of new steroid prescriptions. With regard
to duration of statin therapy, we found that longer duration was associated with the lowest
rates of the primary outcome compared to unexposed persons. Increasing duration reduced
the rate of the secondary outcomes as well, though these estimates were not statistically
significant. Longer duration was associated with the lowest rate of the composite outcome.
When adherence to statin therapy was analyzed, better adherence (MPR >0.90) was
associated with the lowest rate of steroid prescriptions, anti-TNF initiation, abdominal
surgery, hospitalization, and the composite outcome. When stratified by disease type,
increasing dose and duration of statin therapy was associated with the lowest rates of steroid
use for UC, but not CD (data not shown).
Statin type
Of the 6 different statin medications used in this study, simvastatin and atorvastatin were the
most commonly prescribed, representing 40% and 32% of exposures respectively. The HRs
of the primary and secondary outcomes associated with each different statin preparation are
shown in Table 5. Though small size of some strata limited the precision of these estimates,
atorvastatin use was associated with the lowest statistically significant estimate. Simvastatin
was not associated with a reduced rate of steroid usage (HR 0.91 (95% CI 0.74, 1.11)
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Additional sensitivity analyses were performed to further evaluate these findings (Table 6).
To reduce the possibility of contamination of the study population with misdiagnosed or
miscoded IBD, we restricted the cohort to subjects meeting more stringent IBD diagnosis
criteria prior to study which did not change the HR estimates substantially. To evaluate the
effect of statins in younger patients given that the peak incidence of IBD is in the 2nd and 3rd
decades of life, we performed an analysis restricted to patients aged 35-50. In this age-
restricted subset, statins remained associated with a reduced rate of the primary outcome in
all patients. To address the possibility of channeling bias (because statins are frequently
prescribed in patients with metabolic syndrome), we restricted the population to subjects
without any diagnosis of coronary artery disease, diabetes, or stroke. In general, these
restrictions resulted in loss of precision, but the strength of the association remained
unchanged. Because some statin-exposed subjects had a single prescription for statins which
could have occurred in absence of actual exposure or could be associated with only trivial
exposure to statins, we restricted the exposed population to those with >30 days supplied of
statin medication and found the association unchanged. When patients with pre-exposure
steroids were excluded the HR for the primary outcome increased but still remained <1. In
order to evaluate the effect of statins in persons with more quiescent IBD, we excluded those
who were hospitalized in the 180 days prior to starting statins, and those with higher
Charlson comorbidity index (≥2) and found the associations unchanged.
Discussion
In this retrospective cohort study using administrative claims data, we have found that statin
use was associated with a small but measurably decreased rate of steroid prescriptions, a
marker of IBD flares. This association appeared to be strongest in UC patients, but there was
also some evidence of protection in CD patients as well. Statin use tended to decrease the
rates of anti-TNF initiation, abdominal surgery, and hospitalization, but these estimates
generally did not reach statistical significance. Increasing dose and duration of statin therapy
was associated with the lowest rates of steroid initiation, indicating a possible dose-response
phenomenon. The association between statins and reduced steroid use persisted in a number
of sensitivity analyses, indicating that these findings were likely not attributable to bias.
To our knowledge, this is the first large scale epidemiologic study to address the question of
whether statin use is beneficial in IBD patients. If statins are indeed associated with a
steroid-sparing effect and reduced flares in IBD, this could potentially result in reduced
morbidity, reduced toxicity of steroid and immunosuppressant therapy, and reduced costs of
care for IBD sufferers. However, this is an observational study, and our results must be
considered hypothesis-generating until prospective studies are available to confirm or refute
a protective effect of adjunctive statin therapy in IBD.
We found that statin use was associated with a more pronounced effect for ulcerative colitis
vs. Crohn’s disease. This could possibly be explained by several factors. Firstly, since UC
and CD differ in their pathophysiology and treatment, statins may have different effects in
these two diseases. For instance, if the observed effect of statins is due to their anti-
inflammatory actions, statins could be more effective in reducing the mucosal inflammation
seen in UC vs. more transmural inflammation (or fibrotic or fistulizing disease) seen in CD.
Furthermore, steroid use may be a better marker of flares in ulcerative colitis patients than in
Crohn’s patients. Lastly, since we had fewer Crohn’s disease subjects (and fewer statin-
exposed CD subjects) the power for effect estimation was lower for CD than UC, which
resulted in less precision of this HR estimate.
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Based on the stratified analysis of statin-type, while all statin preparations generally resulted
in reduced hazard of the primary outcome, due to limited precision, it’s unclear whether this
represents a class effect for all statins. We found some evidence that atorvastatin may be
associated with the “strongest” protective effect. These data are consistent with other studies
in which atorvastatin has been shown to have anti-inflammatory effects in IBD (17, 22). It is
worth noting that simvastatin was not associated with a reduced rate of steroid usage despite
being the most commonly used statin type.
There are several important strengths to this study. We used a large population
representative of the commercially-insured population of the US in order to maximize
precision and external validity of our results. Also, we used clinically-relevant outcomes that
are likely to be accurately measured with claims data. A “new user” design was used to
avoid the biases associated with prevalent use of exposure medications such as the healthy
user bias. Additionally, we performed an extensive evaluation for potential confounders of
the relationship between statins and IBD flares including demographics, IBD medication
use, comorbidities, and markers of disease severity and healthcare utilization.
There are limitations associated with using administrative claims data, which we attempted
to address with our study design. As with any study using claims data, there exists the
possibility of misclassification bias. In order to minimize misclassification of the study
population, we used a previously reported administrative claims definition for IBD that is
similar or more rigorous that others that have been reported or validated elsewhere (2, 36),
and using a more stringent IBD definition did not change our results. The exposure and
primary outcome were measured by prescriptions filled vs. patient report, which would be
expected to minimize misclassification, but it is possible that some people who were
prescribed statins actually did not take them. To address this possibility, we excluded
persons with a ≤30 day supply, but the HR for the primary outcome was essentially
unchanged. Also, given the limitations of administrative data and the lack of clinical detail,
we were unable to examine the potentially important effects of smoking history, disease
phenotype, or use of non-prescription drugs such as aspirin. Additionally, we recognize that
steroid initiation may be an imperfect marker of flares of IBD, but even in absence of a
100% correlation with flare of disease, steroid use is an important clinical outcome in itself
given the associated toxicities of glucocorticoid therapy.
Because this is an observational study, there are potential systematic differences between
statin users and non-users apart from statin exposure. To address this, our exposed and
unexposed subjects were matched on age, sex, and having a prescription in the same month,
in order to ensure comparability of subjects with respect to demographic characteristics and
access to healthcare. Comorbid illness was included in all models using the Charlson
comorbidity index, a validated measure typically used for this purpose. The positive effect
of statins persisted even after excluding specific populations in which statins are commonly
prescribed (i.e. coronary artery disease, diabetes, or stroke). Nevertheless, it is possible that
residual confounding of the relationship between statins and IBD activity exists that we were
either unable to measure or control for. However, it is worth noting that adjustment for the
confounders we could measure actually strengthened our effect estimates, so it is possible
that if we were able to measure and adjust for more confounders the relationship would be
even stronger.
In conclusion, in this large retrospective cohort study, statin use amongst persons with IBD
was associated with a possible protective, steroid-sparing effect. Prospective controlled
clinical trials are needed to confirm whether adjuvant treatment of IBD patients with statin
drugs may ameliorate flares or spare immunosuppressant therapy.
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Study flow diagram for a historical cohort study of statin use and inflammatory bowel
disease using administrative claims
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Probability of remaining steroid free for subjects with inflammatory bowel disease who
were exposed (black line) and unexposed (gray line) to statin drugs. Curves represent
adjusted Cox Model survival probabilities for the primary outcome (steroid prescription ≥
14 days).
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TABLE 1
Characteristics of the study population
Characteristic Statin exposed (n=1,986) n (%) Unexposed (n=9,871) n (%) p*
Sex 0.9
 Female 1,013 (51.0) 5,025 (50.9)
 Male 973 (49.0) 4,846 (49.1)
Age (years) 1.0
 35-39 108 (5.4) 531 (5.4)
 40-44 177 (8.9) 881 (8.9)
 45-49 303 (15.3) 1,501 (15.2)
 50-54 440 (22.2) 2,188 (22.2)
 55-59 558 (28.1) 2,777 (28.1)
 60-64 400 (20.1) 1,993 (20.2)
Region <0.0001
 Northeast 215 (10.8) 1,190 (12.1)
 North Central 534 (26.9) 2,854 (28.9)
 South 905 (45.6) 3,962 (40.1)
 West 321 (16.2) 1,800 (18.2)
 Unknown/other 11 (0.6) 65 (0.7)
Disease manifestation 0.8
 Crohn’s disease 824 (41.5) 4,176 (42.3)
 Ulcerative colitis 1,132 (57.0) 5,544 (56.2)
 Indeterminate IBD 30 (1.5) 151 (1.5)
Comorbidities† (pre-exposure)
 Coronary artery disease 246 (12.4) 456 (4.6) <0.0001
 Diabetes mellitus 429 (21.6) 918 (9.3) <0.0001
 Stroke 67 (3.4) 112 (1.1) <0.0001
 Charlson index (mean ± SD) 0.65 ± 1.03 0.41 ± 0.93 <0.0001
Disease severity (pre-exposure)
 Weight loss 12 (0.6) 112 (1.1) 0.03
 Malnutrition 5 (0.3) 33 (0.3) 0.6
 Anemia 71 (3.6) 409 (4.1) 0.2
 Abdominal surgery‡ 83 (4.2) 453 (4.6) 0.4
IBD drugs (pre-exposure)
 Oral steroid (≥ 14 days) 341 (17.2) 1,768 (17.9) 0.4
 Anti-TNF 131 (6.6) 513 (5.2) 0.01
 5-ASA 1,718 (86.5) 8,633 (87.5) 0.2
 Azathioprine/6-MP 476 (24.0) 2,209 (22.4) 0.1
 Rectal steroid 112 (5.6) 635 (6.4) 0.2
 Cholestyramine 22 (1.1) 241 (2.4) <0.0001
 Methotrexate 23 (1.1) 123 (1.3) 0.7
 Cyclosporine 19 (1.0) 90 (0.9) 0.8
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Characteristic Statin exposed (n=1,986) n (%) Unexposed (n=9,871) n (%) p*
Healthcare utilization (pre-exposure)
 # outpatient visits (mean ± SD) 11.3 ± 9.3 9.4 ± 8.4 <0.0001
 # hospitalizations (mean ± SD) 0.2 ± 0.5 0.1 ± 0.5 <0.0001
 Any hospitalization 282 (14.2) 1,031 (10.4) <0.0001
 IBD hospitalization 121 (6.1) 566 (5.7) 0.5
Endoscopy (pre-exposure)
 EGD/enteroscopy 168 (8.5) 863 (8.7) 0.7
 Colonoscopy/sigmoidoscopy 759 (38.2) 4,024 (40.8) 0.04
 Any endoscopy§ 794 (40.0) 4,224 (42.8) 0.02
*
p values obtained via Chi-squared tests for categorical variables and Student’s t-tests for continuous variables
†
Identified by any (≥1) associated ICD-9 coded diagnosis
‡
Excluding colectomy/enterostomy and minor/outpatient procedures (e.g. hemorrhoidectomy)
§
Includes EGD, enteroscopy, colonoscopy, or flexible sigmoidoscopy and associated interventions
EGD: Esophagogastroduodenoscopy; IBD: inflammatory bowel disease; Anti-TNF: anti-tumor necrosis factor therapies (i.e. infliximab or
adalimumab); 5-ASA: aminosalicylate drugs (e.g. sulfasalazine); 6-MP: 6-mercaptopurine; SD: standard deviation
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TABLE 2
Hazard Ratios (95% CI) for primary outcome of 1st oral steroid prescription associated with statin exposure in
patients with inflammatory bowel disease overall, and for ulcerative colitis and Crohn’s disease
Exposure
IBD* UC CD
HR (95% CI) HR (95% CI) HR (95% CI)
Statin use
 Unadjusted 0.90 (0.78, 1.04) 0.81 (0.67, 0.99) 1.01 (0.82, 1.24)
 Adjusted 0.82 (0.71, 0.94) 0.75 (0.62, 0.91) 0.91 (0.74, 1.12)
HRs were determined via Cox proportional hazard models, adjusting for the Charlson comorbidity index, pre-exposure use of anti-TNF, 5-ASA, 6-
MP/azathioprine, or rectal steroids, the number of outpatient contacts and hospitalization prior to exposure.
*
IBD includes cases of Crohn’s disease, ulcerative colitis, and indeterminate IBD.
IBD: inflammatory bowel disease; UC: ulcerative colitis; CD: Crohn’s disease; HR: Hazard ratio
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TABLE 3
Hazard Ratios (95% CI) for secondary outcomes of anti-TNF use, abdominal surgery, or hospitalization
associated with statin exposure for all IBD patients, and stratified by ulcerative colitis and Crohn’s disease.
Anti-TNF† Abdominal Surgery‡ Hospitalization Combined§
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
All IBD* 0.72 (0.46, 1.11) 0.80 (0.63, 1.02) 0.88 (0.74, 1.05) 0.88 (0.78, 0.98)
 UC 0.48 (0.19, 1.20) 0.97 (0.69, 1.37) 0.87 (0.67, 1.13) 0.86 (0.74, 1.01)
 CD 0.84 (0.50, 1.40) 0.65 (0.45, 0.93) 0.89 (0.70, 1.13) 0.90 (0.76, 1.07)
HRs were determined via Cox proportional hazard models, adjusting for potential confounders including geographic region, Charlson comorbidity
index, a diagnosis of coronary artery disease, weight loss or anemia, pre-exposure use of aminosalicylates, 6MP or azathioprine, rectal steroids,
outpatient contacts and hospitalizations prior to exposure. The adjustment set differed slightly for each outcome.
*
IBD includes cases of Crohn’s disease, ulcerative colitis, and indeterminate IBD.
†
HRs estimated after excluding subjects who received anti-TNFs in the 180 day pre-exposure period.
‡
Any abdominal surgery (excluding minor outpatient procedures; see Methods section for details of ICD-9 codes used, etc.)
§
First occurrence of any primary or secondary outcome
IBD: inflammatory bowel disease; UC: ulcerative colitis; CD: Crohn’s disease; HR: Hazard ratio
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TABLE 6
Sensitivity analyses for primary outcome
Restricted analysis
IBD UC CD
HR (95% CI) HR (95% CI) HR (95% CI)
More stringent IBD definition* 0.81 (0.69, 0.94) 0.74 (0.60, 0.91) 0.88 (0.70, 1.10)
Age 35-50 only 0.77 (0.61, 0.99) 0.71 (0.50, 1.00) 0.88 (0.62, 1.24)
Exclude CAD 0.82 (0.70, 0.95) 0.77 (0.62, 0.95) 0.91 (0.72, 1.14)
Exclude DM 0.87 (0.74, 1.02) 0.86 (0.70, 1.07) 0.89 (0.70, 1.13)
Exclude Stroke 0.82 (0.71, 0.95) 0.74 (0.61, 0.91) 0.93 (0.76, 1.15)
Exclude CAD, DM, or stroke† 0.87 (0.73, 1.04) 0.86 (0.68, 1.09) 0.92 (0.71, 1.19)
Exclude statin ≤30 days 0.81 (0.70, 0.93) 0.75 (0.61, 0.91) 0.88 (0.71, 1.09)
Exclude pre-exposure steroids 0.95 (0.77, 1.18) 0.92 (0.69, 1.24) 1.03 (0.74, 1.43)
Exclude pre-exposure hospitalization 0.80 (0.68, 0.94) 0.76 (0.61, 0.95) 0.87 (0.69, 1.10)
Charlson index <2 0.82 (0.70, 0.96) 0.77 (0.63, 0.96) 0.87 (0.69, 1.10)
*
Definition included at least 4 diagnosis claims for IBD in addition to at least 1 IBD-related prescription
†
Any subject with a diagnosis claim for coronary artery disease, diabetes, or stroke in the 180 day pre-exposure period was excluded
HRs were determined via Cox proportional hazard models, adjusting for potential confounders including including Charlson comorbidity index,
pre-exposure use of aminosalicylates, 6MP or azathioprine, rectal steroids, outpatient contacts and hospitalizations prior to exposure.
HR: Hazard ratio; IBD: Inflammatory bowel disease; CAD: coronary artery disease; DM: diabetes mellitus; UC: Ulcerative colitis; CD: Crohn’s
disease
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